-up of the effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole . Presented at the 2006 San Antonio Breast Cancer Symposium ; December 14–17, 2006 ; San
Search Results
Allan Lipton, Robert Uzzo, Robert J. Amato, Georgiana K. Ellis, Behrooz Hakimian, G. David Roodman, and Matthew R. Smith
Namratha Vontela, Vamsi Koduri, Lee S. Schwartzberg, and Gregory A. Vidal
testosterone and its derivatives with some clinical efficacy. 2 However, androgen therapy fell out of favor due to concerns of aromatization to its virilizing effects, and the availability of tamoxifen and third-generation aromatase inhibitors (AIs). 3
Laura Spring, Rachel Greenup, Andrzej Niemierko, Lidia Schapira, Stephanie Haddad, Rachel Jimenez, Suzanne Coopey, Alphonse Taghian, Kevin S. Hughes, Steven J. Isakoff, Leif W. Ellisen, Barbara L. Smith, Michelle Specht, Beverly Moy, and Aditya Bardia
TEXT and SOFT trials, more high-risk young women are being treated with ovarian suppression and aromatase inhibitor therapy, which may help improve long-term outcomes for this population moving forward. 23 – 25 In the present study, only approximately
Megan C. Roberts, Allison W. Kurian, and Valentina I. Petkov
. 10.1016/S1470-2045(09)70314-6 20005174 2. Dowsett M , Cuzick J , Ingle J , . Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen . J Clin Oncol 2010 ; 28 : 509 – 518 . 19949017 10.1200/JCO
Sara H. Javid, L. Christine Fang, Larissa Korde, and Benjamin O. Anderson
tamoxifen or an aromatase inhibitor. However, such a change overlooks the significant difference in biological behavior associated with DCIS compared with ADH. ADH incurs a far lower risk of breast cancer, approximately one-half that of low-grade DCIS
Rachel F. Dear, Kevin McGeechan, Megan B. Barnet, Alexandra L. Barratt, and Martin H.N. Tattersall
premenopausal women with early-stage breast cancer; the NCCN Guidelines recommend tamoxifen alone. The AGO guidelines recommend either tamoxifen or an aromatase inhibitor (AI) for postmenopausal women with early-stage breast cancer; the NCCN Guidelines
Melinda L. Telli, William J. Gradishar, and John H. Ward
Endocrine Therapy Still Unclear For postmenopausal HR-positive breast cancer, the most common option, among many, is upfront aromatase inhibitor therapy for 5 years. High-level evidence exists to extend therapy for 5 additional years in select patients, but
William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Janice Lyons, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena S. Moran, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dorothy A. Shead, and Rashmi Kumar
will receive endocrine therapy (tamoxifen or an aromatase inhibitor [AI]; category 1). Adjuvant RT After Mastectomy Multiple trials have reported decrease in locoregional recurrence and OS benefit in patients receiving postmastectomy RT (PMRT
Therese B. Bevers, Deborah K. Armstrong, Banu Arun, Robert W. Carlson, Kenneth H. Cowan, Mary B. Daly, Irvin Fleming, Judy E. Garber, Mary Gemignani, William J. Gradishar, Helen Krontiras, Swati Kulkarni, Christine Laronga, Loretta Loftus, Deborah J. MacDonald, Martin C. Mahoney, Sofia D. Merajver, Ingrid Meszoely, Lisa Newman, Elizabeth Pritchard, Victoria Seewaldt, Rena V. Sellin, Charles L. Shapiro, and John H. Ward
influence of ethnicity and race on the efficacy and safety of raloxifene as a risk reduction agent. Table 4 Rates of Breast Cancer in the NSABP Study of Tamoxifen and Raloxifene (STAR) Trial – 81 Months Median Follow-Up Aromatase Inhibitors
, improved multidisciplinary communication between medical teams and patients, and using 5-FU in the case of cap delay enhanced the delivery of concurrent chemoXRT. AB2018-13. Management of Bone Health in Patients With Breast Cancer on Aromatase Inhibitors
